Indication name: Pompe disease
Pompe disease – Market outlook, Epidemiology, Market Forecast and
Competitive Landscape Report – 2019 To 2030
Thelansis Epidemiology study indicates Pompe disease
affects about 1 in 40,000 people in the United States.
Competitive landscape of includes country specific approved as well as
pipeline therapies. Any asset/ product specific designation or review and
Accelerated Approval are being tracked and supplemented with analyst
commentary.
KOLs insights of Pompe disease across 8 MM market from center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm and Unmet needs.
Pompe disease Market Forecast: Patient Based Forecast Model (MS. Excel
Based Automated Dashboard) which Data Inputs with sourcing , Market Event and
Product Event , Country specific Forecast Model, Market uptake and patient
share uptake , Attribute Analysis , Analog Analysis , Disease burden and
pricing scenario, Summary and Insights.
S. No
Asset
Company Stage
1 AAV2/8LSPhGAA Asklepios
Biopharmaceutical, Inc. Phase 2
2 AT845 Audentes
Therapeutics Phase
2
3 BMN 701 BioMarin
Pharmaceutical
Phase 2
4 alglucosidase alfa Genzyme, a Sanofi
Company Phase 4
5 Rapamycin Lacerta
Therapeutics, Inc Phase 1
6 ATB200, AT2221 Amicus Therapeutics Phase 3
7 SPK-3006 Spark
Therapeutics
Phase 2
No comments:
Post a Comment